Chong Sun
Cytowane przez
Cytowane przez
Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR
A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ...
Nature 483 (7387), 100-103, 2012
Regulation and Function of the PD-L1 Checkpoint
C Sun, R Mezzadra, TN Schumacher
Immunity 48 (3), 434-452, 2018
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118-122, 2014
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
R Mezzadra, C Sun, LT Jae, R Gomez-Eerland, E De Vries, W Wu, ...
Nature 549 (7670), 106-110, 2017
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling
S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ...
Cell 151 (5), 937-950, 2012
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ...
Cell reports 7 (1), 86-93, 2014
Global gene disruption in human cells to assign genes to phenotypes by deep sequencing
JE Carette, CP Guimaraes, I Wuethrich, VA Blomen, M Varadarajan, ...
Nature biotechnology 29 (6), 542-546, 2011
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
C Sun, R Bernards
Trends in biochemical sciences 39 (10), 465-474, 2014
EGFR activation limits the response of liver cancer to lenvatinib
H Jin, Y Shi, Y Lv, S Yuan, CFA Ramirez, C Lieftink, L Wang, S Wang, ...
Nature, 1-5, 2021
RAF suppression synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
S Lamba, M Russo, C Sun, L Lazzari, C Cancelliere, W Grernrum, ...
Cell reports 8 (5), 1475-1483, 2014
BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
K Kemper, O Krijgsman, X Kong, P Cornelissen-Steijger, A Shahrabi, ...
Cell reports 16 (1), 263-277, 2016
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
AI Papadakis, C Sun, TA Knijnenburg, Y Xue, W Grernrum, M Hölzel, ...
Cell research 25 (4), 445-458, 2015
PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition
Z Gao, J Xu, Y Fan, Y Qi, S Wang, S Zhao, X Guo, H Xue, L Deng, R Zhao, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 223, 2022
Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer
Y Guo, J Wang, B Benedict, C Yang, F van Gemert, X Ma, D Gao, H Wang, ...
Genome Medicine 13 (1), 1-15, 2021
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy
H Li, Y., Yang, C., Liu, Z., Du, S., Can, S., Zhang, H., Zhang, L., Huang, X ...
Molecular Cancer, 2022
CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
X Lei, I Khatri, T de Wit, I de Rink, M Nieuwland, R Kerkhoven, ...
Nature Communications 14 (1), 217, 2023
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant
L Correia, R Magno, JM Xavier, BP de Almeida, I Duarte, F Esteves, ...
NPJ Breast Cancer 8 (1), 71, 2022
PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia
H Tsai, Y Wu, R Huang, D Su, Y Wu, X Liu, L Wang, Z Xu, Y Pang, C Sun, ...
Acta Pharmaceutica Sinica B 12 (4), 1913-1927, 2022
Combinations for treatment of cancer
C Sun, R Bernards
US Patent 10,398,696, 2019
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–19